白蛋白结合型紫杉醇(Albumin-Bound Paclitaxel) - 药物靶点：Tubulin_在研适应症：转移性胰腺癌，胰腺癌，转移性胰腺腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Nab-Paclitaxel、Nab-PTX、paclitaxel protein-bound

+ [14]

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [6]

在研适应症

转移性胰腺癌胰腺癌转移性胰腺腺癌+ [34]

非在研适应症

大肠腺癌小肠腺癌腺鳞癌+ [112]

原研机构

Abraxis BioScience, Inc.

在研机构

Teva Pharmaceuticals, Inc.Bristol-Myers Squibb Pharma EEIG

江苏恒瑞医药股份有限公司

+ [11]

非在研机构

GSK Plc

Genentech, Inc.

Novartis AG

+ [12]

权益机构

浙江海昶生物医药技术有限公司

BeOne Medicines Ltd.

科兴生物制药股份有限公司

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (2005-01-07),

转移性乳腺癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

关联

1,677

项与白蛋白结合型紫杉醇相关的临床试验

NCT06592664

/ Withdrawn临床1/2期

A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

开始日期2030-01-01

申办/合作机构

Lisata Therapeutics, Inc.

NCT06998940

/ Not yet recruiting临床3期IIT

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.

开始日期2026-01-06

申办/合作机构

SWOG

[+1]

NCT07033689

/ Not yet recruiting早期临床1期

Open-label, Non-randomized, Single-center Study Investigating the Feasibility, Safety, Tolerability and Efficacy of Suizenji in Unresectable Pancreatic Ductal Adenocarcinoma Patients

This is a feasibility, safety, tolerability, and efficacy research study of an investigational device called "Suizenji", an ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system for the treatment of unresectable pancreatic ductal adenocarcinoma. Focused ultrasound therapy uses a number of small ultrasound generators attached to a bowl-shaped ultrasound generator to emit ultrasound waves from outside to inside the body and focus them on a single point where cancerous cells in the pancreas are located. The targeted area is then heated, which kills the pancreatic cancer cells, and as a result, the patient's life may be prolonged. Experience with Suizenji for pancreatic cancer patients has shown that the "heating" is only a warm feeling in the abdomen during the treatment.

开始日期2025-12-01

申办/合作机构

Sonire Therapeutics Inc

100 项与白蛋白结合型紫杉醇相关的临床结果

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的转化医学

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的专利（医药）

登录后查看更多信息

43,062

项与白蛋白结合型紫杉醇相关的文献（医药）

2025-12-31·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies

Article

作者: Bartuzi, Damian ; Stepulak, Andrzej ; Kalafut, Joanna ; Okon, Estera ; Wawruszak, Anna ; Czerwonka, Arkadiusz ; Luszczki, Jarogniew

Sirtuins (SIRTs) are NAD+-dependent histone deacetylases, which play a key role in cancer progression; however, their prognostic values in breast cancer (BC) remain a subject of debate and controversy. Accumulative evidence suggests that each sirtuin possesses individual character, implicating its role in the regulation of multifaceted biological functions leading to BC initiation, progression and metastasis. Selisistat (EX527) is a potent, cell permeable, highly selective SIRT1 inhibitor. In the study, the tumour-suppressive effects of the SIRT1 inhibitor EX527 (selisistat) alone and in combination with paclitaxel (PAX) in different breast cancer cell lines and zebrafish xenograft models were investigated. The type of pharmacological drug-drug interaction between EX527 and PAX was determined using the isobolographic method. EX527 and PAX used individually inhibited proliferation, induced apoptosis and caused cell cycle arrest in G1 and subG1/G2 phases. Interestingly, the combination of these compounds used in the 1:1 dose-ratio augmented all these effects (IC_50add 29.52 ± 3.29 - 38.45 ± 5.26). The co-treatment of EX527 with PAX generated desirable additive drug-drug interaction. The simultaneous application of EX527 and PAX induced a stronger inhibition of tumour growth compared to individual treatments in zebrafish xenografts. In silico analysis revealed a protein-protein interaction pathway (SIRT1-AKT-S1PR1-GNAI1/GNAO1-Tubulin) connecting molecular targets of both ligands. To summarise, the combination of EX527 and PAX more effectively impairs breast cancer cell growth compared to individual treatments. However, further investigations are required to clarify the specific targets and molecular mechanisms underlying the activity of EX527:PAX in other preclinical models.

2025-12-01·Journal of Gastrointestinal Cancer

The Efficacy and Safety of Nivolumab Combined with Nab-Paclitaxel or Oxaliplatin as a First-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Article

作者: Li, Shuman ; Ye, Sisi ; Li, Juan ; Zhang, Ying ; Liu, Rongrui ; Shi, Weiwei

OBJECTIVE:

This study aims to assess the therapeutic efficacy and safety of nivolumab combined with chemotherapy as a first-line treatment for advanced or metastatic gastric cancer, specifically comparing the outcomes of oxaliplatin-based versus albumin-bound paclitaxel (nab-paclitaxel)-based therapies.

METHODS:

We retrospectively analyzed 93 patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma treated at the First Medical Center of Chinese PLA General Hospital from September 2017 to November 2022. Patients were categorized into the nivolumab + oxaliplatin (N-OX group) or nivolumab + nab-paclitaxel (N-AP group) based on the chemotherapy regimen. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety were evaluated as endpoints.

RESULTS:

At the end of the follow-up period on September 31, 2023, we reported an ORR of 65.6% and DCR of 95.7% across all patients. The median PFS was 8.4 months, with no significant difference between the N-OX and N-AP groups (median, 7.8 vs 9.5 months; P = 0.450). Notably, patients with diffuse gastric cancer in N-AP group showed a 44.7% reduction in tumor progression risk compared with the N-OX group (P = 0.046). The overall safety profile was acceptable in two groups.

CONCLUSIONS:

Our study suggested that nivolumab combined with chemotherapy was effective and safe as a first-line intervention for advanced gastric cancer. While both oxaliplatin and nab-paclitaxel regimens showed similar efficacy, the nab-paclitaxel may offer additional benefits for patients with diffuse gastric cancer. Further research is encouraged to confirm these findings and refine treatment strategies.

2025-12-01·MOLECULAR BIOLOGY REPORTS

Human papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro

Article

作者: Selander, Katri ; Jukkola, Arja ; Ravaioli, Sara ; Parviainen, Essi ; Manninen, Aki ; Nurmenniemi, Sini ; Bravaccini, Sara

Abstract:

Background:

Toll-like receptor 9 (TLR9) is a DNA recognizing receptor expressed also in several cancers. Decreased TLR9 expression is associated with poor prognosis in triple negative breast cancer (TNBC), but the role of TLR9 in breast cancer pathophysiology is currently unclear. Regulation of TLR9 expression in breast cancer is poorly understood. Human papillomavirus (HPV) infections suppress TLR9 expression in cervical cancers but the association between HPV and breast cancer has remained controversial. The aim of this study was to test if HPV16 can suppress TLR9 expression in breast cancer cells and affect cell behavior.

Methods and results:

Human T-47D and MDA-MB-231 breast cancer cells were transduced with lentivirus encoding HPV16 E6 oncoprotein. The effects of E6 on TLR9 mRNA and protein expression, and cell proliferation, migration, invasion and sensitivity to chemotherapy were studied in vitro. Breast cancer tissue samples (n = 37) were analyzed for the presence of HPV DNA. E6 expression decreased TLR9 mRNA expression in MDA-MB-231 and T-47D cells in hypoxia. E6 expression altered breast cancer cell proliferation and made cells significantly less sensitive to the growth inhibitory effects of chemotherapeutic agents. HPV L1 gene was not detected in a small pilot cohort of clinical breast cancer specimens.

Conclusion:

HPV16 may influence breast cancer cell TLR9 transcription and chemotherapy responses and could thereby affect breast cancer prognosis. These results suggest that HPV may have a previously unrecognized role in breast cancer pathophysiology and warrant further studies on the topic.

1,432

项与白蛋白结合型紫杉醇相关的新闻（医药）

2025-07-15

·药明康德

显著延长癌症患者总生存期！潜在重磅小分子有望上市

▎药明康德日前，Corcept Therapeutics已向美国FDA提交其专有选择性皮质醇调节剂relacorilant的新药申请（NDA），用于治疗铂类耐药卵巢癌患者。此外，relacorilant用于治疗内源性高皮质醇症（又称库欣综合征，Cushing’s syndrome）的NDA也正在接受FDA审评。值得一提的是，该疗法获行业媒体Evaluate评选为2025年潜在重磅疗法之一。该新药申请主要基于关键性3期ROSELLA试验和2期试验的积极数据。在这些试验中，接受relacorilant联合白蛋白紫杉醇治疗的铂类药物耐药卵巢癌患者在无进展生存期（PFS）和总生存期（OS）方面均优于单独接受白蛋白紫杉醇治疗的患者，且患者无需进行生物标志物筛选。▲Relacorilant延长患者的PFS（图片来源：参考资料[2]）分析显示，ROSELLA试验达成了其主要终点——由盲法独立中央评审（BICR）评估的无进展生存期显著改善。与单药治疗相比，relacorilant联合白蛋白紫杉醇治疗使疾病进展风险降低了30%（风险比：0.70；p=0.0076）。Relacorilant联合疗法组患者的中位PFS-BICR延长至6.5个月，而白蛋白紫杉醇单药治疗患者为5.5个月。此外，由研究者评估的PFS结果与PFS-BICR一致，风险比为0.71（p=0.0030）。在总生存期的中期分析中，添加relacorilant使患者的死亡风险降低了31%，显著延长了患者的生命。Relacorilant联合疗法组的中位OS为16.0个月，而白蛋白紫杉醇单药组为11.5个月（风险比：0.69；p=0.0121）。这一疗效结果在所有具有临床相关的亚组中均有体现，包括预后较差的患者群体。▲Relacorilant延长患者的OS（图片来源：参考资料[2]）Relacorilant联合白蛋白紫杉醇治疗具有良好的耐受性，治疗组之间的安全性表现相当。添加relacorilant并未增加患者的安全性负担。▲Relacorilant的安全性结果（图片来源：参考资料[2]）Relacorilant是一款口服、潜在“first-in-class”的选择性糖皮质激素受体（GR）拮抗剂，通过与GR结合而非与体内其他激素受体结合，从而调节皮质醇活性。Corcept Therapeutics正在将relacorilant用于卵巢癌及其他多种严重疾病的开发，包括内源性高皮质醇症和前列腺癌。该疗法已获FDA和欧盟委员会（EC）分别授予用于治疗高皮质醇症的孤儿药资格，并被欧盟委员会授予治疗卵巢癌的孤儿药资格。作为用于治疗高皮质醇症患者的药物，FDA已受理relacorilant的NDA，PDUFA日期为2025年12月30日。参考资料：[1] Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer. Retrieved July 15, 2025 from https://ir.corcept.com/news-releases/news-release-details/corcept-submits-new-drug-application-relacorilant-treatment-0[2] ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer. Retrieved July 15, 2025 from https://corcept.com/wp-content/uploads/ASCO2025-1.pdf[3] Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer. Retrieved July 15, 2025 from https://ir.corcept.com/news-releases/news-release-details/corcept-presents-pivotal-clinical-data-asco-late-breaker免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床2期孤儿药临床结果临床3期

2025-07-15

·今日头条

绝境逢生！铂耐药卵巢癌新药获美国FDA批准，12个月生存率达60%

卵巢癌是导致女性癌症死亡的第五大常见原因。接受含铂疗法后六个月内复发的患者被定义为“铂耐药”卵巢癌，这类患者治疗选择有限，复发后单药化疗的中位总生存期仅约12个月。 2025年7月14日，抗癌领域传来振奋消息：美国FDA受理了针对铂耐药性卵巢癌药物——relacorilant的新药申请（NDA），该药此前已获FDA孤儿药资格认定。这一进展为长期面临治疗困境的铂耐药卵巢癌患者点亮了新希望，为患者带来延长生存期、改善生活质量的精准治疗新选择！ ▲截图源自“OncLive” Relacorilant联合疗法将铂耐药卵巢癌生存期延长近5个月，12个月OS率达60% Relacorilant是Corcept公司研发的一款口服选择性糖皮质激素受体（GR）拮抗剂（SGRA），通过特异性结合GR调节皮质醇活性（不作用于其他激素受体），可增强肿瘤对化疗诱导细胞凋亡的敏感性，目前正开发用于卵巢癌、前列腺癌等治疗。该药的新药申请（NDA）获关键性3期ROSELLA试验（NCT05257408）积极数据支持。该研究纳入381例既往接受过紫杉烷类和贝伐单抗治疗（其中61%曾接受PARP抑制剂治疗）的女性患者，随机分为两组：联合治疗组（relacorilant+白蛋白结合型紫杉醇，n=188）、白蛋白结合型紫杉醇单药组（n=193）。结果显示：联合治疗组疗效显著优于单药组：中位无进展生存期（PFS）延长至6.54个月（95%CI,5.55-7.43），而单药组PFS仅为5.52个月（95%CI,3.94-5.88）（HR=0.70，P=0.0076），且 PFS率也更高，6个月PFS率分别为52%（联合治疗组）vs 42%（单药治疗组），12个月PFS率分别为25%（联合治疗组）vs 13%（单药治疗组）。 ▲图源“JCO”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除中期分析显示，联合治疗组中位总生存期（OS）显著延长至16.0个月，单药组仅为11.5个月，HR=0.69，95%CI:0.52-0.92，P=0.01）， 12个月OS率达60%，单药组仅为49% 。此外，联合治疗组客观缓解率（ORR）在数值上更高（36.9% vs 30.1%），且未增加额外安全风险。小编寄语近年来，卵巢癌的治疗已经取得了长足的进展，逆转了晚期患者的生存期，除了上面整理的内容，还有更多的新药正在研发中。如果您想了解卵巢癌更多抗癌新药/新技术的更多讯息，可将治疗经历、近期病理检查报告、出院小结等，提交至全球肿瘤医生网医学部，进行初步评估。参考资料 [1]Olawaiye A,et al. ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72)[J]. 2025. https://ascopubs-org.libproxy1.nus.edu.sg/doi/10.1200/JCO.2025.43.17_suppl.LBA5507 [2]https://www.onclive.com/view/fda-receives-nda-for-relacorilant-in-platinum-resistant-ovarian-cancer 本文为全球肿瘤医生网原创，未经授权严禁转载

孤儿药临床结果临床3期

2025-07-15

·今日头条

WT1-DC疫苗联合化疗逆转癌王耐药困局，胰腺癌中位总生存超3年

胰腺导管腺癌（PDAC）是一种死亡率极高的恶性肿瘤，其显著特征是对细胞毒性化疗和放射疗法存在固有耐药性。这一特性导致无法切除的胰腺导管腺癌（UR-PDAC）患者临床治疗效果不佳，因此，研发既针对肿瘤细胞、又能靶向肿瘤微环境（TME）的新型疗法，成为改善患者预后的迫切需求。近日，《免疫肿瘤学杂志》报道了一项突破性研究：应用多功能 WT1-DC 疫苗治疗不可切除晚期胰腺导管腺癌（UR-PDAC）的 Ⅰ 期临床试验，公布了令人振奋的初步数据 —— 所有入组患者中位OS超3年、PFS超2年！WT1-DTH 长期阳性患者生存期更是达4.5 年！这一突破为长期困于治疗绝境的晚期胰腺癌患者点亮了跨越数年的生存希望，让难治性胰腺癌的治疗迎来了值得期待的新曙光！ ▲截图源自“PMC” WT1-DC疫苗联合化疗让晚期患者肿瘤负荷大降，生存期达3.52年，中位无进展生存期达2.23年 WT1是一种与血管生成、肿瘤进展、侵袭及转移密切相关的转录因子，在肿瘤发生中发挥致癌作用。它不仅表达于胰腺导管腺癌（PDAC）细胞，还存在于肿瘤微环境（TME）的癌症干细胞、髓系抑制细胞（MDSC）及肿瘤血管中，这使其成为极具潜力的癌症治疗靶点。而树突状细胞（DC）作为专业抗原呈递细胞，在启动和调节肿瘤相关抗原特异性免疫反应中起着关键作用。基于此，研究团队开发出一种新型WT1肽脉冲树突状细胞（WT1-DC）疫苗，Ⅰ期临床研究数据同步发表于《免疫肿瘤学杂志》中。该研究共纳入10例不可切除晚期胰腺导管腺癌（UR-PDAC）患者，包括6例局部晚期胰腺导管腺癌（LA-PDAC）、3例转移性胰腺导管腺癌（M-PDAC）、1例术后复发患者，均经病理确诊为腺癌，且表达WT1和MHCⅠ类分子。入组后，先接受白蛋白结合型紫杉醇+吉西他滨联合化疗，再接受WT1-DC疫苗治疗。结果显示：在9例可评估预后的患者中，WT1肽特异性迟发型超敏反应（WT1-DTH）长期阳性患者（n=4）的临床疗效显著优于短期阳性患者（n=5），且所有WT1-DTH长期阳性患者的生存期均达到至少4.5年。此外，所有患者的肿瘤负荷均有下降（降幅0.0%-57.4%）（详见下图）。 ▲图源“J Immunother Cancer”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除其中 7例患者（6例局部晚期胰腺导管腺癌、1例转移性胰腺导管腺癌）实现部分缓解（PR），其余 3例维持长期疾病稳定（SD）。治疗约6个月后，患者肿瘤最大标准摄取值（SUVmax）显著下降（p=0.006）。下图展示了4例不可切除晚期胰腺导管腺癌（UR-PDAC）患者（编号WT1-DC-01、WT1-DC-03、WT1-DC-05、WT1-DC-09），在接受治疗前后的CE-CT与¹⁸F-FDGPET/CT影像对比，清晰展示了治疗带来的变化。 ▲图源“J Immunother Cancer”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除此外，生存数据更为亮眼： 9例患者的中位无进展生存期（PFS）达2.23年，中位总生存期（OS）达3.52年（详见下图A）。其中， 5例局部晚期胰腺导管腺癌（LA-PDAC）患者的中位PFS为2.48年，总生存期尚未达到；而 3例转移性胰腺导管腺癌（M-PDAC）患者的中位PFS达1.37年、中位OS达2.41年（详见下图B）。 ▲图源“J Immunother Cancer”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除综上，通过WT1-DC疫苗联合化疗的免疫治疗方案，可强效激活UR-PDAC患者的WT1特异性免疫反应，有望调节肿瘤微环境并为部分患者争取转化手术机会，最终带来显著的临床获益。小编寄语树突状细胞（DC）作为体内唯一能激活初始T细胞的抗原提呈细胞，在免疫反应中占据核心地位。目前，DC疫苗虽多数仍处于早期临床试验阶段，但已在部分国家正式应用于临床。对于早期肿瘤患者，术后采用DC疫苗联合放化疗的辅助治疗方案，可通过清除残留癌细胞、形成免疫记忆，降低复发转移风险。目前，树突状疫苗在日本、德国等，用于临床辅助治疗多种癌症，包括皮肤癌、肝癌、肺癌、肾癌、乳腺癌等。想了解树突状细胞疫苗等抗癌新技术更多讯息的患者，可将近期病理报告、影像学检查资料、治疗经历等，提交至全球肿瘤医生网医学部，进行初步评估或了解详细的入排标准。参考资料 [1]Koido S,et al.Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer. J Immunother Cancer. 2024 Oct 8;12(10):e009765. https://pmc-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/articles/PMC11474828/ 本文为全球肿瘤医生网原创，未经授权严禁转载

临床结果疫苗放射疗法临床2期临床3期

100 项与白蛋白结合型紫杉醇相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
转移性胰腺癌	秘鲁	浙江海昶生物医药技术有限公司	2025-05-14
胰腺癌	中国	Bristol Myers Squibb Co.	2024-01-05
转移性胰腺腺癌	美国	Teva Pharmaceuticals, Inc.	2023-05-11
不能切除性胰腺癌	日本	Taiho Pharmaceutical Co., Ltd.	2014-12-18
胃癌	日本	Taiho Pharmaceutical Co., Ltd.	2013-02-21
乳腺癌	中国	Abraxis BioScience, Inc.	2008-06-30
非小细胞肺癌	欧盟	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	冰岛	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	挪威	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	欧盟	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	冰岛	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	挪威	Bristol-Myers Squibb Pharma EEIG	2008-01-11
转移性乳腺癌	美国	Bristol Myers Squibb Co.	2005-01-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期乳腺癌	临床3期	中国	石药集团欧意药业有限公司	2023-04-27
进展期胃腺癌	临床3期	中国	石药集团欧意药业有限公司	2020-03-01
PD-L1阳性三阴性乳腺癌	临床3期	阿根廷	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	智利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	捷克	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	法国	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	匈牙利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	意大利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	墨西哥	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	秘鲁	Hoffmann-La Roche, Inc.	2019-12-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03377491 (PANOVA-3, ASCO2025) 人工标引	临床3期	晚期胰腺导管腺癌	571	TTFields + gemcitabine/nab-paclitaxel (GnP)	糧鹽壓艱觸遞齋觸範餘(膚艱襯襯衊廠構蓋顧醖) = 壓鹹鏇艱築繭廠壓淵網築製顧廠憲窪餘選襯鑰 (鹹簾簾膚鹹憲遞簾淵壓, 15.0 ~ 18.0) 更多	积极	2025-06-04
				Gemcitabine/nab-paclitaxel (GnP)	糧鹽壓艱觸遞齋觸範餘(膚艱襯襯衊廠構蓋顧醖) = 夢鹽襯製窪觸獵鹽鬱糧築製顧廠憲窪餘選襯鑰 (鹹簾簾膚鹹憲遞簾淵壓, 12.8 ~ 15.4) 更多
NCT04390958 (Pubmed \| Int J Surg)	临床2期	局部晚期食管鳞状细胞癌新辅助	-	Albumin-bound paclitaxel plus cisplatin and capecitabine (APC regimen)	構積繭範鑰鬱鬱鬱糧蓋(繭膚餘鏇鬱壓鏇膚鏇糧) = 築鏇顧廠製繭壓壓淵夢壓襯遞襯顧簾憲遞蓋艱 (築蓋蓋構艱顧廠觸觸鹽, 18.8% ~ 38.6) 更多	积极	2025-06-01
				Placebo	憲衊繭壓醖鬱網齋遞衊(鑰選選願膚蓋製鹽獵襯) = 壓衊觸獵鑰選獵選窪壓淵襯範網窪顧鑰艱顧壓 (廠衊艱選網壓夢網網鹽 ) 更多
ASCO2025	临床1/2期	晚期胰腺腺癌	-	Gemcitabine/nab-paclitaxel (GN)	積構網簾淵願遞衊憲鹹(窪糧膚願鏇鹽鬱齋範鹽): HR = 5.2 (95% CI, 0.63 ~ 0.92), P-Value = 0.01	积极	2025-05-30
				GN/cisplatin (GCN)
NCT04247165 (LAPTOP, ASCO2025)	临床1/2期	转移性胰腺癌	55	Nivolumab	鹽糧顧糧繭鬱構鏇願顧(簾夢願鬱鑰壓積襯鹽製) = 網願築選鏇製鏇選醖構餘積簾膚齋網齋築襯夢 (築糧構膚鬱衊簾鑰艱鹽, 53.3 ~ 90.2) 更多	积极	2025-05-30
				Ipilimumab	鹽糧顧糧繭鬱構鏇願顧(簾夢願鬱鑰壓積襯鹽製) = 鬱鹹醖繭膚網夢鑰鏇鹹餘積簾膚齋網齋築襯夢 (築糧構膚鬱衊簾鑰艱鹽, 42.2 ~ 78.2) 更多
NCT05218889 (NCT05218889, ASCO2025)	临床1/2期	转移性胰腺导管腺癌一线 M1/M2 macrophage percentages	96	NASCA regimen (Surufatinib, Camrelizumab, Nab-Paclitaxel, S-1)	憲鬱壓蓋壓顧廠鑰淵蓋(範顧選糧糧鏇鹽鹹鹹餘) = 獵鏇夢網齋憲夢鏇齋糧獵鑰鹽鑰餘鏇醖築鬱壓 (遞簾範蓋襯願襯餘簾鹹 ) 更多	积极	2025-05-30
				AG regimen (Nab-Paclitaxel, Gemcitabine)	憲鬱壓蓋壓顧廠鑰淵蓋(範顧選糧糧鏇鹽鹹鹹餘) = 構衊衊襯顧艱選鏇構窪獵鑰鹽鑰餘鏇醖築鬱壓 (遞簾範蓋襯願襯餘簾鹹 ) 更多
ASCO2025	N/A	晚期胆道癌二线	84	Nab-paclitaxel-based chemotherapy + ICI	網鹽製襯艱淵積範範獵(積鏇願網範鑰鹽願糧鏇) = 壓壓壓範壓製願鏇襯築選窪範蓋糧觸製遞簾窪 (遞構鹽窪遞鹽願範獵積 ) 更多	积极	2025-05-30
				Nab-paclitaxel-based chemotherapy	網鹽製襯艱淵積範範獵(積鏇願網範鑰鹽願糧鏇) = 窪窪鹹鏇膚鏇憲築膚憲選窪範蓋糧觸製遞簾窪 (遞構鹽窪遞鹽願範獵積 ) 更多
NCT03678883 (1801 part 3B, ASCO2025)	临床2期	转移性胰腺导管腺癌 CA 19-9 levels \| IFNβ \| PD-L1	-	Elraglusib 9.3 mg/kg IV once weekly + Gemcitabine/nab-paclitaxel	艱願膚襯壓齋餘夢醖簾(窪壓糧簾醖顧餘窪觸鏇) = 製淵選獵製遞鏇積製鏇網夢淵選遞觸範獵積窪 (選憲夢醖齋鑰淵觸築餘 ) 更多	积极	2025-05-30
				Gemcitabine/nab-paclitaxel	艱願膚襯壓齋餘夢醖簾(窪壓糧簾醖顧餘窪觸鏇) = 餘鑰糧餘選願築鏇醖鏇網夢淵選遞觸範獵積窪 (選憲夢醖齋鑰淵觸築餘 ) 更多
NCT05669482 (RAMP 205, ASCO2025)	临床1/2期	转移性胰腺导管腺癌一线 activating KRAS mutations	54	Avutometinib/Defactinib + Gemcitabine/nab-paclitaxel	夢蓋壓窪積製醖網繭網(鏇鏇繭鹽憲憲選廠膚簾) = 41% 餘製繭構齋範憲選襯鹽 (蓋壓窪餘築鏇觸壓遞範 ) 更多	积极	2025-05-30
NCT02767557 (Pubmed \| J Clin Oncol)	临床2期	胰腺癌一线 growth differentiation factor 15 (GDF15)	147	Gemcitabine/nab-paclitaxel with Tocilizumab	膚艱積鹹鬱憲窪選繭膚(膚夢願膚膚鑰衊鏇獵觸) = 網壓鑰構製壓遞簾鏇顧鑰願築膚鏇網鏇觸構蓋 (獵鏇壓壓衊顧壓鹹鏇繭, 56.3 ~ 78.1) 更多	积极	2025-05-12
				Gemcitabine/nab-paclitaxel without Tocilizumab	膚艱積鹹鬱憲窪選繭膚(膚夢願膚膚鑰衊鏇獵觸) = 憲範鏇選襯壓築積網繭鑰願築膚鏇網鏇觸構蓋 (獵鏇壓壓衊顧壓鹹鏇繭, 49.6 ~ 72.1) 更多
NCT05673811 (VIRAGE, GlobeNewswire) 人工标引	临床2期	转移性胰腺癌一线	96	VCN-01 + Gemcitabine/nab-paclitaxel	齋範廠醖願淵糧願簾獵(選繭鹽襯築構範築鬱鬱) = 顧鏇壓淵範蓋衊淵鹹齋構願壓鏇憲糧鏇築淵醖 (鬱積簾築積繭觸鹹窪壓 ) 达到更多	积极	2025-05-07
				Gemcitabine/nab-paclitaxel	齋範廠醖願淵糧願簾獵(選繭鹽襯築構範築鬱鬱) = 窪遞鬱齋壓齋願壓窪鬱構願壓鏇憲糧鏇築淵醖 (鬱積簾築積繭觸鹹窪壓 ) 达到更多